Events
FT Global Pharma & Biotechnology Conference 2019
Addressing disruption and transformation in pharma
11–12 Nov 2019 | Royal Lancaster, London
This industry-leading event brings together executives from the world’s largest pharmaceutical and biotechnology companies, their health care counterparts, and other key stakeholders across the life sciences value chain to deliberate on key trends and issues that are set to reshape the life sciences sector.
Disruption will continue to take center stage in the life sciences economy for the rest of 2019 and beyond. The sector is constantly evolving all while addressing some significant issues—pricing pressures in many parts of the world, growth in a number of markets, competition from new entrants in the prevention and wellness space, and rise of pricey, potentially curative gene and cell therapies—creating a vacuum for transformation, while generating opportunities and challenges for stakeholders in their journey of care delivery. Executives from across the industry are set to come together at the 37th edition of the FT Global Pharmaceutical and Biotechnology Conference to discuss these trends and more and discuss how to create a successful economic model for life sciences ecosystem of the future.
Visit the FT's conference page for more information on speakers.
25 percent registration discount
(Use code Deloitte25 when registering)
To register for the conference and learn about the speakers, agenda, and topics, visit:
https://live.ft.com/Events/2019/FT-Global-Pharmaceutical-and-Biotechnology-Conference
Key issues to be addressed at the conference:
- Transformation and talent strategies
- Chief digital officer forum
- Pharma’s pricing conundrum
- Alternative funding models for R&D
- Intellectual property
- Rewarding innovation and the regulation we need
- Digital R&D
- The global competition for investment
- Innovation on the frontiers or science, medicine and technology
- What pharma needs to do better at telling its story
Deloitte sessions
11 November 2019 | 1:35 p.m.
Panelists:
- Camilla Sylvest, EVP, Commercial Strategy and Corporate Affairs, Novo Nordisk
- Lord Drayson, PhD, CEO, Sensyne Health
- Eddie Martucci, Co-Founder and CEO, Akili Interactive
- Hanno Ronte, Partner, Deloitte
- Dan Vahdat, Founder, Medopad
Moderator:
- Sarah Neville, Global Pharmaceuticals Editor, Financial Times
11 November 2019 | 3:15 p.m.
Session keynote:
- Marie-France Tschudin, President, Novartis Pharmaceuticals
Panelist:
- Mark Howells, Vice President, Global Talent and Development, AstraZeneca
- Bahija Jallal, CEO, Immunocore
- Niren Thanky, Consultant & Global Pharmaceutical Practice Leader, Spencer Stuart
- Hans Trees, Global Head of Pharma Communications and Strategy, Roche
Moderator:
- Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
12 November 2019 | 9:20 a.m.
Panelists:
- Mark Trusheim, Strategic Director, NEWDIGS, MIT Centre for Biomedical Innovation
- Yvonne Greenstreet, Chief Operating Officer, Alnylam
- Marc Funk, Chief Executive Officer, Lonza Group
- Justin McCarthy, Senior Vice President, Patient and Health Impact Group, Pfizer
- Ilona Torontali, Global Head Access Centre of Excellence for Pricing, HTA, Evidence and Policy, Roche
Moderator:
- Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
12 November 2019 | 11:35 a.m.
Panelists:
- Virginia Acha, Global Regulatory Policy for Europe, Middle East, Africa and Asia, MSD
- Thomas Senderovitz, Director General, Danish Medicines Agency
- Arthur Lahr, CEO, Kiadis Pharma
- Aisling Burnand, CEO, Association of Medical Research Charities (AMRC)
Moderator:
- Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
12 November 2019 | 9:05 a.m.
Keynote Address:
Joaquin Duato, Vice Chairmam of the Executive Committee, Johnson & Johnson
Moderator:
Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
Eminence
Explore our most recent insights:










Recommendations
Medtech and the Internet of Medical Things
How connected medical devices are transforming health care
2020 Global life sciences outlook
Creating new value | Building blocks for the future